{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:20:12Z","timestamp":1784841612218,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clinbiochem.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T10:47:40Z","timestamp":1629802060000},"page":"82-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discordant SOX-1 antibodies results in paraneoplastic Lambert-Eaton syndrome diagnosis by the clinical laboratory"],"prefix":"10.1016","volume":"97","author":[{"given":"Adela","family":"Pozo-Giraldez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-6704","authenticated-orcid":false,"given":"Enrique","family":"Rodr\u00edguez-Borja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Diaz-Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-7214","authenticated-orcid":false,"given":"Arturo","family":"Carratala-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Magro-Pose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Perez-Griera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinbiochem.2021.08.004_b0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0165-5728(00)00431-8","article-title":"Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line","volume":"113","author":"Benatar","year":"2001","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2021.08.004_b0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ncl.2018.01.008","article-title":"Lambert-Eaton myasthenic syndrome","volume":"36","author":"Kesner","year":"2018","journal-title":"Neurol. Clin."},{"issue":"9","key":"10.1016\/j.clinbiochem.2021.08.004_b0015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/jnnp.54.9.764","article-title":"Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients","volume":"54","author":"Elrington","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.clinbiochem.2021.08.004_b0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3988\/jcn.2020.16.4.530","article-title":"Anti-SOX1 antibodies in paraneoplastic neurological syndrome","volume":"16","author":"Sun","year":"2020","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.clinbiochem.2021.08.004_b0025","doi-asserted-by":"crossref","unstructured":"M. Tschernatsch, O. Gross, N. Kneifel, M. Kaps, F. Blaes, SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun. Rev. 8(7), (2009) 549\u201351.","DOI":"10.1016\/j.autrev.2009.01.015"},{"key":"10.1016\/j.clinbiochem.2021.08.004_b0030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2021.08.004_b0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jneuroim.2010.07.005","article-title":"Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy","volume":"226","author":"Tschernatsch","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2021.08.004_b0040","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2169\/internalmedicine.5934-20","article-title":"Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome with SOX-1","volume":"60","author":"Wada","year":"2021","journal-title":"Intern. Med."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.08.004_b0045","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1212\/NXI.0000000000000701","article-title":"Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes","volume":"7","author":"D\u00e9chelotte","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clinbiochem.2021.08.004_b0050","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3389\/fimmu.2019.00769","article-title":"Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations","volume":"10","author":"Ruiz-Garc\u00eda","year":"2019","journal-title":"Front Immunol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021002253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021002253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:57:16Z","timestamp":1757865436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912021002253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":10,"alternative-id":["S0009912021002253"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.08.004","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discordant SOX-1 antibodies results in paraneoplastic Lambert-Eaton syndrome diagnosis by the clinical laboratory","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}